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Abstract: The widespread use of gene expression analyses has been limited by 
the lack of critical evaluations of the methods used to extract nucleic acids 
from human tissues. For evaluating gene expression patterns in whole blood or 
leukocytes, the method of RNA isolation needs to be considered as a critical 
variable in the design of the experiments. Quantitative real-time PCR (qPCR) 
is widely used for the quantification of gene expression in today’s clinical prac-
tice. Blood samples as a preferred RNA source for qPCR should be carefully 
handled and prepared in order not to inhibit gene expression analyses. The pre-
sent study was designed to compare the frequently employed guanidine thio-
cyanate–phenol–chloroform-based method (TRI Reagent®) with two alterna-
tive RNA isolation methods (6100 PrepStation and QIAamp®) from whole 
blood or leukocytes for the purpose of gene expression analysis in chronic 
myeloid leukemia (CML) patients. Based on the results of this study, for the 
best combination of yield and RNA extraction purity, taking into account the 
necessary amount of the clinical sample and performance time, the protocol 
using phenol-based TRI Reagent® for RNA extraction from leukocytes is 
suggested as the most suitable protocol for this specific gene expression ana-
lysis. 
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INTRODUCTION 
The development of molecular medicine, particularly in the last decade, un-
doubtedly put new molecular diagnostic tests into the focus. Most of these tests 
employ some kind of gene expression analysis. The widespread use of gene ex-
pression analyses has been limited by the lack of critical evaluation of the me-
thods used to extract nucleic acids from human tissues. Quantitative real-time 
                                                                                                                    
* Corresponding author. E-mail: ksenija.jakovljevic@ncrc.ac.rs 
# Serbian Chemical Society member. 
_________________________________________________________________________________________________________________________
2010 Copyright (CC) SCS
Available online at www.shd.org.rs/JSCS/1054 JAKOVLJEVIĆ et al. 
PCR (qPCR) is widely used for the quantification of gene expression in today’s 
clinical practice.1 Blood is an easy to obtain tissue and reflects the relevant in-
formation about the body, which makes it the preferred source of RNA for diag-
nostic tests. Blood samples for qPCR should be carefully handled and prepared 
so as not to inhibit gene expression analysis.2 The absence of widely accepted 
protocols for blood sampling and further RNA extraction among laboratories is 
evident. Each laboratory has to establish the optimal procedure for the specific 
clinical application. 
For evaluating gene expression patterns in whole blood or leukocytes, the 
method of RNA isolation needs to be considered as a critical variable in the de-
sign of the experiments.3 Low quality and quantity of RNA often make all down-
stream applications impossible to conduct. Inadequate sampling, shipping and 
handling could easily cause degradation of RNA.4 It is crucial to decrease the 
sampling time to a minimum and preferably store samples in RNA later.5 Clini-
cal samples of limited quantity are specially challenging, since unsuccessful RNA 
isolation means that the opportunity to analyze that particular sample is irretri-
evably lost. 
Phenol-based methods are most commonly used for RNA isolation. When 
dealing with small clinical samples, a single extraction reagent (such as phenol- 
-based TRI Reagent®) is crucial in order to obtain sufficient material for subse-
quent analyses.6 Due to the high activity of RNAses in tissues, it is necessary to 
include a strong chaotropic (biologically disruptive) agent into the isolation re-
agent mixture. Guanidinium salts, together with phenol and chloroform (added to 
improve the deproteinization efficacy of phenol) denature and precipitate pro-
teins without altering the solubility of RNA.7 
In our laboratory, monitoring of the minimal residual disease in patients 
diagnosed with chronic myeloid leukemia (CML) is performed by detection of 
the bcr-abl fusion-gene (specific for chromosomal translocation t (9:22)) by 
qPCR.8 The present study was designed to compare the mentioned guanidine 
thiocyanate–phenol–chloroform-based method with two alternative methods for 
RNA isolation from whole blood or leukocytes in order to establish the most ade-
quate one for this specific downstream qPCR. To validate the quality of isolation 
process, both the yield and the purity of RNA were assessed and also the quality 
control of cDNA synthesis was performed by PCR amplification of reference 
genes. As a result of this evaluation, subsequent qPCR analysis was successfully 
conducted (the results are not included in this manuscript). 
EXPERIMENTAL 
Patient and control samples 
The current study included five control (healthy) subjects and fourteen patients with 
CML. The patients were under medical treatment for CML and had been under constant ob-
servation for detection of minimal residual disease in our laboratory for several months. From 
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each control and patient, 20 mL EDTA blood were drawn by venipuncture and further pro-
cessed within a few hours. According to the RNA isolation protocols from whole blood, spe-
cified amounts of blood, just from control samples, were transferred immediately into separate 
tubes and processed the same day. The rest of the blood was used for leukocyte isolation by 
centrifugation, according to the established procedure used in our laboratory. The isolated 
cells were counted and pellets were stored at –70 °C until RNA isolation. 
RNA isolation 
Three methods for extraction of total cellular RNA from blood and leukocytes were eva-
luated. The isolations were performed following the manufacturers’ instructions with minor 
modifications.  
Whole blood RNA isolation 
Total RNA samples were isolated from whole blood only from the controls using TRI 
Reagent® BD kit (Sigma) (the TRI Reagent®), Applied Biosystems Total RNA Isolation 
Chemistry kit for Abi Prism™ 6100 Nucleic Acid PrepStation (the 6100 PrepStation) and 
QIAamp® RNA Blood Mini kit (Qiagen) (the QIAamp®). Briefly, 200 µL of the blood samp-
les were lysed in TRI Reagent® BD supplemented with 5 M acetic acid, and the lysate was 
separated into aqueous and organic phases via chloroform addition and centrifugation. The 
RNA sample was then precipitated from the aqueous phase by 2-propanol and solubilized 
with 40 µL RNAase-free water. For the standard RNA isolation protocol on the 6100 PrepSta-
tion, 200 µL of the blood samples were lysed and purified using Applied Biosystems Total 
RNA isolation chemistry. For the QIAamp® method, the protocol for human whole blood was 
realized without any modification using 1 mL of blood as the starting material. The extracted 
RNA was eluted in 40 µL RNAase-free water. 
Leukocyte RNA isolation 
Total RNA samples were isolated from leukocytes from four controls (the fifth had to be 
discarded) and from all CML patients using the same methods, performing the protocols for 
whole blood according to the manufacturers’ recommendations with minor modifications. The 
only difference in the phenol-based method was the first step, in which the cells (5×106 cells 
from controls; 107 cells from patients) were lysed with TRI Reagent® (Sigma) (TRI Rea-
gent®). Aliquots of 2.1×106 and 1.3×106 cells from controls and patients, respectively, were 
taken for the standard RNA isolation protocol on the 6100 PrepStation. Finally, aliquots of 
5×106 cell pellets from controls and patients were dissolved in 1 mL of normal saline solution 
and further processed according to the QIAamp® protocol for whole blood. This additional 
step was performed in order to selectively lyse the remaining erythrocytes in the pellets. 
RNA quantization and visualization 
The total RNA of each sample was quantified using a spectrophotometer (Eppendorf 
BioPhotometer) by the ultraviolet light absorbance at 260 nm. The ratio A260/A280 was used to 
assess the purity of the isolated RNA. The RNA concentration was calculated in μg µL-1. To 
analyze the RNA banding pattern, gel electrophoresis (Pharmacia Biotech) in 2 % agarose 
gels with ethidium bromide was performed. The RNA samples (6 µL) mixed with xylene cya-
nol color (3 µL; 0.25 % xylene cyanol in 30 % glycerol in water) and 0.5-μL portion (1.0 μg 
µL-1) of molecular weight marker 1 kb DNA Ladder (Invitrogen) were run in 0.5xTBE buffer 
for 50 min at 25 mA. The RNA bands were visualized on a UV transilluminator (Hoefer) and 
photographed using a Nikon D70s camera. 
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cDNA Synthesis and PCR 
cDNA synthesis (RT-PCR) from total RNA and following PCR reactions with Abl and 
p53 primers were performed only for the control (n = 4) and patient (n = 14) samples isolated 
from leukocytes by the TRI Reagent® method. 
To perform RT-PCR with random primers, 2 μg of total RNA were used as template for 
MultiScribe™ Reverse Transcriptase (50 U μL-1) in a High-Capacity cDNA Reverse Trans-
cription kit (Applied Biosystems) according to manufacturer’s instructions. The reaction mix-
tures (20 µL) were incubated in a Mastercycler gradient (Eppendorf). cDNAs were analyzed 
by 2 % agarose gel electrophoresis and visualized on a UV transilluminator. 
The PCR step was performed in a volume of 25 μL, including 2 μl 100 ng μL-1 of cDNA, 
12.5 μL of AmpliTaq Gold PCR Master Mix (Applied Biosystems), 1 μL 10 pmol μL-1 each 
of the two Abl primers (Applied Biosystems) and 0.8 μL 10 pmol μL-1 each of the two p53 
primers (Applied Biosystems). A tube with water instead of cDNA was used as the negative 
control (NTC – non-template control) in both PCR reactions. The sequence of the forward 
PCR primer for Abl was TGGAGATAACACTCTAAGCAT, whereas the sequence of the 
reverse PCR primer for Abl was GATGTAGTTGCTTGGGACCCA. The sequences of the 
forward and reverse PCR primers for p53 were ACTGGCCTCATCTTGGGCCT and 
TGTGCAGGGTGGCAAGTGGC, respectively. PCR for Abl was performed in a Master-
cycler gradient for 30 s denaturation at 95 °C followed by 35 cycles consisting of 30 s at 94 
°C, 1 min at 65 °C, 1 min at 72 °C and a hold at 16 °C. For the p53 PCR, the reaction 
mixtures were heated at 95 °C for 5 min and then subjected to 35 cycles at 95 °C for 1 min 
and at 60 °C for 1 min, followed by a hold at 4 °C in the same thermal cycler. A 6-μL portion 
of PCR products and 3-μL portion of ready-to-use molecular weight marker O’Gene Ruler 
100 bp DNA Ladder (Fermentas) were analyzed by 40 min agarose electrophoresis. The PCR 
product bands were visualized on a UV transilluminator and photographed. A sample was 
considered positive for Abl when it generated a PCR product of the expected size of 123 bp in 
the Abl PCR reaction, whereas the generated product of 171 bp in p53 PCR reaction indicated 
a sample positive for p53. 
RESULTS AND DISCUSSION 
The RNA concentrations and A260/A280 ratios of each control and patient 
sample obtained using the TRI Reagent
®, 6100 PrepStation and QIAamp® me-
thod are given in Table I. In all tested samples, the highest concentration was 
achieved with the TRI Reagent® (between 0.888 and 6.338 μg μL–1), while with 
QIAamp®, it was much lower (between 0 and 0.197 μg μL–1). The 6100 Prep-
Station system showed a poor performance (between 0 and only 0.012 μg μL–1). 
The average RNA concentrations for each method are shown in Fig. 1. There is a 
clear difference in mean RNA concentrations between the TRI Reagent® method 
and the other two methods (those obtained using the TRI Reagent® were noti-
ceably higher). The results also show the difference between concentrations of 
the RNA samples isolated from blood and those from leukocytes (the blood RNA 
concentrations were lower). 
One of possible explanations for the highest yield of RNA obtained with TRI 
Reagent® could be the amount of the starting material, as well as the different 
biochemical mechanism of cell lysis. In the cases of QIAamp® and the 6100 
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PrepStation, we were limited at the beginning by the maximum amount of start-
ing material, recommended by manufacturer. 
TABLE I. Concentrations and purity of the RNA samples 
Material Samples 
c / μg μL
-1 (A260/A280 ratio) 
RNA isolation methods 
TRI Reagent® 6100  PrepStation  QIAamp® 
Blood 
Controls (n = 5)  C1  1.293 (1.43)  0.004 (NA)
a 0.076  (1.38) 
  C2  2.176 (1.75)  0.004 (NA)  0.163 (1.27) 
  C3  2.711 (1.53)  0.000 (NA)  0.061 (1.92) 
  C4  2.422 (1.55)  0.000 (NA)  0.062 (1.74) 
  C5  2.007 (1.52)  0.000 (NA)  0.082 (1.71) 
Leukocytes 
Controls (n = 4)  C1  2.096 (1.50)  0.000 (NA)  0.012 (NA) 
  C2  3.211 (1.57)  0.012 (NA)  0.197 (1.38) 
  C3  3.611 (1.59)  0.000 (NA)  0.092 (1.54) 
  C5  3.397 (1.54)  0.000 (NA)  0.072 (1.59) 
Patients (n = 14)  1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
4.100 (1.48) 
2.014 (1.57) 
4.189 (1.55) 
3.333 (1.49) 
3.801 (1.47) 
6.338 (1.57) 
3.458 (1.47) 
3.538 (1.46) 
0.888 (1.37) 
1.818 (1.43) 
3.039 (1.50) 
2.263 (1.41) 
4.574 (1.50) 
3.517 (1.51) 
0.008 (0.29) 
0.000 (NA) 
0.000 (NA) 
0.000 (NA) 
0.004 (NA) 
0.000 (NA) 
0.000 (NA) 
0.000 (NA) 
0.000 (NA) 
0.000 (NA) 
0.000 (NA) 
0.000 (NA) 
0.000 (NA) 
0.000 (NA) 
0.016 (NA) 
0.000 (NA) 
0.000 (NA) 
0.000 (NA) 
0.008 (NA) 
0.050 (1.80) 
0.008 (NA) 
0.036 (NA) 
0.032 (NA) 
0.000 (NA) 
0.000 (NA) 
0.024 (3.03) 
0.016 (NA) 
0.000 (NA) 
aNot available, A280 = 0 
The A260/A280 ratios (Table I) had values lower than 2.0 (the expected value 
for a pure RNA sample) for most of the samples (just one sample had an 
A260/A280 ratio 3.0). The QIAamp® method resulted in the highest values, rang-
ing from 1.3 to 3.0, but many of the samples even had no available value (NA) 
because A280 was zero. For the TRI Reagent® method, these values ranged from 
1.4 to 1.8 and practically all values for 6100 PrepStation, except one (0.3), were 
NA. The highest purity of RNA obtained by the QIAamp® method was expected 
due to high selective binding properties of the silica-based membrane, but the 
yield of RNA, regardless of its purity, was not sufficient for further cDNA syn-
thesis and expression analysis by qPCR. During the isolation procedure with TRI 
Reagent®, one ethanol washing of the RNA pellet was omitted in an effort to ma-
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ximize the yield, which may be the reason of the lower purity RNA. The 6100 
PrepStation employs selective precipitation of RNA and its physical capture on a 
membrane, giving the possibility of isolating very pure RNA but, except in a few 
cases, measurable values of the RNA concentration were not obtained. 
 
Fig. 1. Obtained RNA concentrations, the resulting bars shown are the average, and the 
standard deviation, from values obtained for each extraction method. 
In order to verify the integrity, all RNA samples for each of the extraction 
methods were analyzed using 2 % agarose gel electrophoresis. High quality RNA 
was indicated by visible bands on the agarose gels only for certain methods. 
Agarose gel electrophoresis of isolated control RNA samples is shown in Fig. 2. 
 
Fig. 2. Agarose gel electrophoresis of isolated control RNA samples. A) Whole blood; 
B) leukocytes. 1) TRI Reagent®, 2) QIAamp® and 3) 6100 PrepStation. 
C1–C5: control subjects, M: molecular weight marker. 
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From whole blood control samples, RNA bands are visible only for the QIAamp® 
method, while from leukocytes control samples, they are also visible for the 
QIAamp® and TRI Reagent® methods. Clearly, the RNA obtained from leuko-
cytes showed more defined and visible bands, indicating a low level of degra-
dation. Therefore, it was decided to use leukocytes as the RNA source. The RNA 
band patterns for patient samples isolated from leukocytes by the TRI Reagent® 
and QIAamp® methods are shown in Fig. 3 (the agarose gel for the 6100 Prep-
Station method is not shown because there were no visible RNA bands). The 
RNA bands obtained by QIAamp® are more defined than those obtained by TRI 
Reagent®, due the higher purity of the former, but the problem of the amount 
remains. Since the next step of the analysis is RT-PCR, which requires in this 
specific case 2 μg of RNA (in order to obtain the minimal amount of cDNA for 
qPCR), it is evident that the QIAamp® method would not provide enough RNA 
from all samples. Although some control and patient samples may have sufficient 
RNA concentrations when obtained by the QIAamp® method, it is crucial that 
the method of choice always provides the necessary amounts of RNA. On the 
other hand, the TRI Reagent® method consistently provided sufficient amounts 
of RNA for all the analyzed samples and was therefore chosen as the most ade-
quate protocol for this specific purpose. 
 
Fig. 3. Agarose gel electrophoresis of patients’ RNA samples isolated from leukocytes. 
1) TRI Reagent® and 2) QIAamp®. 1–14: Patients. 
Following electrophoresis, RNA obtained with TRI Reagent® from leukocy-
tes from each control and patient subject were assayed in RT-PCR, as described 
in the Experimental (results not shown). The synthesized cDNAs were further 
amplified with Abl and p53 primers in separate PCR reactions according to the 
protocol described in the Experimental. Agarose gels with PCR product bands 
and DNA molecular weight marker are represented in Fig. 4. PCR products of 
123 bp in the Abl PCR reaction and of 171 bp in the p53 PCR reaction were 
obtained in practically all tested samples. The fact that visible bands of PCR pro-
ducts for both genes were obtained indicates that there are no inhibitors in temp-
late RNA preparations and that obtained cDNA was of satisfactory quality for 
further analysis. The subsequent gene expression analysis by qPCR for the detec-
tion of the bcr–abl fusion transcript was successfully performed on all patient 
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cDNA samples (the results are not shown). This diagnostic procedure is a part of 
everyday clinical routine in our laboratory. 
 
Fig. 4. Agarose gel electrophoresis of PCR products; 1) Abl gene primers and 2) p53 gene 
primers. M: Molecular weight marker; NTC: non-template control. 
C1, C2, C3, C5: Control subjects; 1–14: patients. 
CONCLUSIONS 
In light of the obtained results for the best combination of yield and RNA 
extraction purity, taking into account the required amount of the clinical sample 
and the performance time, the protocol using the phenol-based TRI Reagent® for 
RNA extraction from leukocytes is suggested as the most suitable protocol for 
this specific gene expression analysis. 
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ИЗВОД 
ПОРЕЂЕЊЕ ФЕНОЛСКЕ СА АЛТЕРНАТИВНИМ МЕТОДАМА ИЗОЛАЦИЈЕ РНК 
У СВРХУ АНАЛИЗЕ ГЕНСКЕ ЕКСПРЕСИЈЕ  
КСЕНИЈА В. ЈАКОВЉЕВИЋ, МИЛЕНА Р. СПАСИЋ, ЕМИНА Ј. МАЛИШИЋ, ЈЕЛЕНА Д. ДОБРИЧИЋ, 
АНА М. КРИВОКУЋА и РАДМИЛА Н. ЈАНКОВИЋ 
Odeqewe za eksperimentalnu onkologiju, Institut za onkologiju i radiologiju Srbije, 
Pasterova 14, 11000 Beograd 
Недостатак критичне процене ефикасности метода за изолацију нуклеинских киселина 
из ткива ограничава шире коришћење анализа генске експресије. Изолација РНК представља 
критичну променљиву при одређивању генске експресије из узорака крви или леукоцита. 
Квантитативни „real-time“ PCR (qPCR) се у савременој клиничкој пракси често користи за 
квантификацију генске експресије. Узорци крви, као најчешћи извор РНК, морају бити паж-
љиво припремљени да не би дошло до инхибиције анализе генске експресије у току qPCR-а. 
Ова студија је спроведена у циљу упоређивања често коришћене гванидин-тиоцијанат–фе-
нол–хлороформске методе изолације (TRI Reagent®) са друге две алтернативне методе за 
изолацију РНК (6100 PrepStation и QIAamp®) из пуне крви или леукоцита у сврху анализе 
генске експресије код пацијената са хроничном мијелоидном леукемијом. Имајући у виду 
количину клиничког узорка и време потребно за анализу, фенолска метода (TRI Reagent®) је 
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дала најбољу комбинацију приноса РНК и њене чистоће, те се стога ова метода предлаже за 
изолацију РНК из леукоцита у сврху ове специфичне клиничке анализе. 
(Примљено 23. децембра 2009, ревидирано 5. фебруара 2010) 
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